Clinical Drug Investigation

, Volume 28, Issue 4, pp 251–261 | Cite as

Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder

A 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial
  • Changsu Han
  • Chi-Un Pae
  • Bun-Hee Lee
  • Young-Hoon Ko
  • Prakash S. Masand
  • Ashwin A. Patkar
  • Sook-Haeng Joe
  • In-Kwa Jung
Original Research Article

Abstract

Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15).

Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n = 50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n = 39/50 [78%]; venlafaxine: n = 32/45 [71%]).

Results: The mean total score on the PHQ-15 decreased by 34.7% (−8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (−6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by −4.9 (29.4%, p < 0.0001) and −13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by −4.3 (26.2%, p = 0.001) and −9.02 (46.0%, p < 0.0001), respectively, in the venlafaxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated.

Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.

References

  1. 1.
    Schappert SM. National ambulatory medical care survey: 1989 summary. Vital Health Stat 13; 1992 Apr (110): 1-80Google Scholar
  2. 2.
    Hartz AJ, Noyes R, Bentler SE, et al. Unexplained symptoms in primary care: perspectives of doctors and patients. Gen Hosp Psychiatry 2000 May–Jun; 22(3): 144–52PubMedCrossRefGoogle Scholar
  3. 3.
    de Waal MW, Arnold IA, Eekhof JA, et al. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004 Jun; 184: 470–6PubMedCrossRefGoogle Scholar
  4. 4.
    Khan AA, Khan A, Harezlak J, et al. Somatic symptoms in primary care: etiology and outcome. Psychosomatics 2003 Nov-Dec; 44(6): 471–8PubMedCrossRefGoogle Scholar
  5. 5.
    Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003; 12(1): 34–43PubMedCrossRefGoogle Scholar
  6. 6.
    Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999 Oct 28; 341(18): 1329–35PubMedCrossRefGoogle Scholar
  7. 7.
    Wells KB, Rogers W, Burnam A, et al. How the medical comorbidity of depressed patients differs across health care settings: results from the Medical Outcomes Study. Am J Psychiatry 1991 Dec; 148(12): 1688–96PubMedGoogle Scholar
  8. 8.
    Beekman AT, Penninx BW, Deeg DJ, et al. Depression and physical health in later life: results from the Longitudinal Aging Study Amsterdam (LASA). J Affect Disord 1997 Dec; 46(3): 219–31PubMedCrossRefGoogle Scholar
  9. 9.
    Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004 Jan–Feb; 66(1): 17–22PubMedCrossRefGoogle Scholar
  10. 10.
    Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry 1991 Jan; 148(1): 34–40PubMedGoogle Scholar
  11. 11.
    Smith Jr GR, Monson RA, Ray DC. Patients with multiple unexplained symptoms: their characteristics, functional health, and health care utilization. Arch Intern Med 1986 Jan; 146(1): 69–72PubMedCrossRefGoogle Scholar
  12. 12.
    Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol 2005 Mar; 20(2): 87–91PubMedCrossRefGoogle Scholar
  13. 13.
    Terre L, Poston WS, Foreyt J, et al. Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom 2003 Sep–Oct; 72(5): 261–7PubMedCrossRefGoogle Scholar
  14. 14.
    Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002 May; 180: 396–404PubMedCrossRefGoogle Scholar
  15. 15.
    Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001 Mar; 178: 234–41PubMedCrossRefGoogle Scholar
  16. 16.
    Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001 Jul; 179: 15–22PubMedCrossRefGoogle Scholar
  17. 17.
    Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62(2): 190–8PubMedCrossRefGoogle Scholar
  18. 18.
    Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66(2): 238–47PubMedCrossRefGoogle Scholar
  19. 19.
    Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004 Oct; 24(5): 488–96PubMedCrossRefGoogle Scholar
  20. 20.
    Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007 Feb; 164(2): 290–300PubMedCrossRefGoogle Scholar
  21. 21.
    Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60Suppl. 22: 23–8PubMedGoogle Scholar
  22. 22.
    Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004 Aug; 19(6): 387–96PubMedCrossRefGoogle Scholar
  23. 23.
    Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352–9PubMedCrossRefGoogle Scholar
  24. 24.
    Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24(1): 1–14PubMedCrossRefGoogle Scholar
  25. 25.
    Pollack MH, Worthington 3rd JJ, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32(4): 667–70PubMedGoogle Scholar
  26. 26.
    Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006 Oct; 63(10): 1158–65PubMedCrossRefGoogle Scholar
  27. 27.
    Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006 Jun; 26(3): 259–67PubMedCrossRefGoogle Scholar
  28. 28.
    Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003 Sep–Oct; 10(5): 318–23PubMedCrossRefGoogle Scholar
  29. 29.
    Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18(2): 131–7PubMedGoogle Scholar
  30. 30.
    Galvez R, Caballero J, Atero M, et al. Venlafaxine extended release for the treatment of chronic pain: a series of 50 cases [in Spanish]. Actas Esp Psiquiatr 2004 Mar–Apr; 32(2): 92–7PubMedGoogle Scholar
  31. 31.
    Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004 May; 24(5): 621–9PubMedCrossRefGoogle Scholar
  32. 32.
    Pernia A, Mico JA, Calderon E,.et al. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000 Jun; 19(6): 408–10PubMedCrossRefGoogle Scholar
  33. 33.
    Kroenke K, Messina 3rd N, Benattia I, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 2006 Jan; 67(1): 72–80PubMedCrossRefGoogle Scholar
  34. 34.
    Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006 Feb; 22(2): 257–64PubMedCrossRefGoogle Scholar
  35. 35.
    Kuiken TA, Schechtman L, Harden RN. Phantom limb pain treatment with mirtazapine: a case series. Pain Pract 2005 Dec; 5(4): 356–60PubMedCrossRefGoogle Scholar
  36. 36.
    Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002 May; 23(5): 442–7PubMedCrossRefGoogle Scholar
  37. 37.
    Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002 Mar–Apr; 64(2): 258–66PubMedGoogle Scholar
  38. 38.
    Association AP. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press 1994Google Scholar
  39. 39.
    Beck AT, Steer RA. Manual for the Beck Depression Inventory. San Antonio (TX): Psychological Corporation 1993Google Scholar
  40. 40.
    Goldberg D. General Health Questionnaire (GHQ-12). Windsor: NFER-Nelson 1992Google Scholar
  41. 41.
    Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002 Sep–Oct; 10(5): 541–50PubMedGoogle Scholar
  42. 42.
    Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comor-bid generalized anxiety disorder. J Clin Psychiatry 2001 Jul; 62(7): 523–9PubMedCrossRefGoogle Scholar
  43. 43.
    Arnold LM, Pritchett YL, D’Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007 Oct; 16(8): 1145–56CrossRefGoogle Scholar
  44. 44.
    Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004 Oct; 19Suppl. 1: S27–35PubMedCrossRefGoogle Scholar
  45. 45.
    Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004 Aug; 19(8): 813–8PubMedCrossRefGoogle Scholar
  46. 46.
    Kroenke K. Somatoform disorders and recent diagnostic controversies. Psychiatr Clin North Am 2007 Dec; 30(4): 593–619PubMedCrossRefGoogle Scholar
  47. 47.
    Escobar JI, Gara MA, Diaz-Martinez AM, et al. Effectiveness of a time-limited cognitive behavior therapy type intervention among primary care patients with medically unexplained symptoms. Ann Fam Med 2007 Jul–Aug; 5(4): 328–35PubMedCrossRefGoogle Scholar
  48. 48.
    O’Malley PG, Balden E, Tomkins G, et al. Treatment of fibro-myalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000 Sep; 15(9): 659–66PubMedCrossRefGoogle Scholar
  49. 49.
    Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990 Jul; 82(1): 34–8PubMedCrossRefGoogle Scholar
  50. 50.
    Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992 May; 49(2): 205–19PubMedCrossRefGoogle Scholar
  51. 51.
    Jackson JL, O’Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006 Mar; 11(3): 212–22PubMedGoogle Scholar
  52. 52.
    O’Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999 Dec; 48(12): 980–90PubMedGoogle Scholar
  53. 53.
    de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 2007 May 10; 24(1): 36–41PubMedCrossRefGoogle Scholar
  54. 54.
    Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998 Mar; 59(3): 116–22PubMedCrossRefGoogle Scholar
  55. 55.
    Samuelian JC, Hackett D. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998; 12(3): 273–8PubMedCrossRefGoogle Scholar
  56. 56.
    Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003 Aug; 64(8): 921–6PubMedCrossRefGoogle Scholar
  57. 57.
    Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. dic Antidepressant Study Group Int Clin Psychopharmacol 1999 Nov; 14(6): 329–37PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Changsu Han
    • 1
    • 2
  • Chi-Un Pae
    • 2
    • 3
  • Bun-Hee Lee
    • 1
  • Young-Hoon Ko
    • 1
  • Prakash S. Masand
    • 1
  • Ashwin A. Patkar
    • 1
  • Sook-Haeng Joe
    • 1
  • In-Kwa Jung
    • 1
  1. 1.Department of PsychiatryKorea University, College of MedicineSeoulKorea
  2. 2.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA
  3. 3.Department of Psychiatry, Kangnam St Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea

Personalised recommendations